Spotlight on Orthopedics

Credits: 1.25 AANP / CME
PsA+COVID-19: Virtual Solutions and Personalized Learning That Optimize Psoriatic Arthritis Care
Philip Mease, MD, MACR
AKH Inc., Advancing Knowledge in Healthcare

PsA+COVID-19: Virtual Solutions and Personalized Learning That Optimize Psoriatic Arthritis Care

Start

Activity Details

Free CME/AANP
1.25 AMA PRA Category 1 Credit(s)
1.25 Contact Hour(s)
Released: April 12, 2021
Expires: April 12, 2022
75 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

  • Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  • Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
  • Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.

Activity Description

The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.

To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.

Agenda

  1. Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
  2. Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
  3. Personalized Patient Cases
  4. Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time

Faculty

Philip Mease, MD, MACR
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington


Alvin F. Wells, MD, PhD, FACR
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
  • Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Faculty (Presenter): Phillip Mease, MD, MACR

  • Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
  • Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB

Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi

Faculty (Planner): Richard Martin, MD, MA

  • Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly

Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP

  • Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designated this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
AANPThis activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Activity Details

Free CME/AANP
1.25 AMA PRA Category 1 Credit(s)
1.25 Contact Hour(s)
Released: April 12, 2021
Expires: April 12, 2022
75 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

  • Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  • Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
  • Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.

Activity Description

The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.

To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.

Agenda

  1. Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
  2. Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
  3. Personalized Patient Cases
  4. Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time

Faculty

Philip Mease, MD, MACR
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington


Alvin F. Wells, MD, PhD, FACR
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
  • Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Faculty (Presenter): Phillip Mease, MD, MACR

  • Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
  • Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB

Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi

Faculty (Planner): Richard Martin, MD, MA

  • Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly

Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP

  • Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designated this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
AANPThis activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Orthopedics Presentations

No programs are available for this specialty. Check back later.